NeuroTimone Facility (PFNT)

The PFNT Facility is a coherent set of exploration tools in neurobiology allowing research at the molecular, cellular and integrated levels.

News

  1. Hervé Kovacic elected president of the CNU section 85

    Professor of Biophysics and Biomathematics at the Faculty of Pharmacy of Marseille, Hervé Kovacic is elected for a six-year term. Section CNU 85 manages the qualifications, promotions and bonuses of teacher-researchers specializing in physicochemical sciences and applied engineering in health. Doctor Pascale Barbier, also from team 9 of INP has been nominated as a member of the same CNU section.

  2. Jean-Michel Paumier successfully defended his doctoral thesis

    Jean-Michel Paumier, former PhD student in Team 1 (Neural Plasticity and Degeneration), has successfuly defended his thesis on Wednesday the 05th of December 2018. After few hours of a nice presentation followed by many questions, the examining board congratulated Jean-Michel for his good work and granted him the diploma of doctor in Neuroscience.

  3. 3 PhD students of the INP participate in the Neuroschool PhD Days 2018

    On December 6 and 7, 2018, Neuroschool PhD Days took place. In this edition entitled "Through the looking glass: beyond our reality", second-year neuroscience PhD students  were invited to present their work.

    It is in this context that the 3 PhD students of the INP took part: Laurie Arnaud, Audrey Jacq and Dominika Pilat.

  4. Vect-Horus announces agreement with Johnson & Johnson innovation

    Vect-Horus announced today the signing of a research collaboration agreement with Janssen Pharmaceuticals, Inc. one of the Janssen Pharmaceutical Companies of Johnson & Johnson. The goal of this collaboration is to use Vect-Horus’ proprietary technology to transport various Janssen monoclonal antibodies to the brain for the treatment of neurodegenerative diseases. This deal was facilitated by Johnson & Johnson Innovation Limited.

  5. Santiago Rivera gave two conferences on Alzheimer's disease

    The first conference entitled “Alzheimer’s disease, fears and hopes” was given at the meeting of the management boards of the french Vaincre l’Alzheimer and the german Alzheimer Forschung Initiative foundations that was held on November 16th 2018 at the Novotel Hotel Marseille Vieux Port.

    The second conference, in the context of the Conferences Cycle of the Institute of Neurosciences of the University of Barcelona, was entitled “ Membrane type-matrix metalloproteinases are newcomers to the Alzheimer’s field ”  ans was held on November 20th at the School of Pharmacy of the University of Barcelona.

  6. New article from the Neural Degeneration and Plasticity team

    The latest work from the Neural Degeneration and Plasticity team, in collaboration with the BBB and neuroinflammation team of Michel Khrestchatisky: "The pro-amyloidogenic effects of Membrane-type 1-Matrix Metalloproteinase involve MMP-2 and BACE-1 activities, and the modulation of APP trafficking" is now published in the FASEB Journal (doi: 10.1096/fj.201801076R). Our data unveil new mechanistic insights supporting the pro-amyloidogenic role of MT1-MMP based on APP processing and trafficking, and reinforces the idea that MT1-MMP may become a new potential therapeutic target in Alzheimer’s disease. 

  7. 6th French Biacore User Meeting

    Géraldine Ferracci, manager of the Surface Plasmon Resonance unit at INP's Plateform Interactome Neuro-Timone (PINT), gave a talk at the 6th Biacore Users' Meeting. During her presentation untitled "Contribution of the SPR in the study of membrane proteins: from their quantification to the optimization of therapeutic peptide vectors", she stressed the role of this major biophysical technique, played in the therapeutic approaches developed within the INP.

  8. Yvon Berland and Alexandre Tokay, respectively President of AMU and CEO of Vect-Horus signed a Public-Private Partnership allowing Vect-Horus to settle its research activities in the La Timone Medical Faculty

    Vect-Horus has established a long-term highly efficient collaboration with the Institute of NeuroPhysiopathology INP (UMR7051 CNRS-AMU) directed by Dr. Michel KHRESTCHATISKY, cofounder of the company, and this Partnership signed on November 14, 2018 is a cornerstone in the creation of the LABCOM (Common Research Lab) between the INP and Vect-Horus.

Pages

INP in numbers

  • 126 members
  • 44 researchers
  • 48 research assistants
  • 12 post-docs
  • 11 PhD

 

New publication for the Neuro-inflammation and Multiple Sclerosis team (INP team 5) in Cytokine about the immunomonitoring of infliximab biotherapies

In this paper, Daniel Bertin evaluated the immunological follow-up of patients suffering from chronic inflammatory diseases and receiving anti-TNF biotherapy. Three commercial ELISA assays for monitoring soluble through levels of infliximab and anti-infliximab antibodies in serum showed a good global correlation of results. However, some quantitative discrepancies could change clinical decision. As a consequence, Daniel Bertin recommended to keep the same kit to perform a longitudinal follow-up of patients.

Undefined

Aurélie Tchoghandjian-Auphan, CRCN CNRS from the GlioME team, was recently granted by ARC fondation for her project "Effects of Smac mimetics treatment on glioblastomas immune response" .

Aurélie Tchoghandjian-Auphan, CRCN CNRS from the GlioME team, in the Insitute of NeuroPhysiopathology, UMR CNRS 7051, was recently granted by ARC fondation for her project "Effects of Smac mimetics treatment on glioblastomas immune response".

Subsequently she was interviewed by :
France 3  (JT 19/20 PACA diffusion du 15/11: 7'09 à 9'45) ; 
Provence Azur (18/11/2019) ;
20 Minutes Marseille (18/11/2019)
- La Provence

 

Undefined

GlioME team in collaboration with INT (Institute of Neurosciences Timone) published a new study in Journal of Neuroinflammation on the effect of Bevacizumab on glioblastoma-bearing mice, using 2-photon imaging

Our data show that VEGF blockade leads to an increased recruitment of monocytes and to an adjustment of dendritic cell subsets’ profiles, differing in their ability to induce an adaptive immune response. Altogether, they provide important new insights into the effects of Bevacizumab at the cellular level and into the spatio-temporal evolution of intra-tumoral innate immune cell densities.

Undefined

Marseille - Cassis 2019

Congratulations to all the CNRS team for running the Marseille-Cassis race two weekends ago, and especially to Claude Villard (7th from the left, top row), INP team 9 and PINT facility member who ran this semi-marathon in 1 hour and 48 minutes.

Next year, let's make a whole INP team (as usual, the race will take place on the last Sunday of October)!

For more information, head to the race's official website.

Undefined

Listening to our molecular clocks

During the NeuroStories event, held on Monday October 7 at the Faculty of Medicine, Anne-Marie François Bellan gave a remarkable stand up on how our body vibrates to the rhythm of internal chronometers called circadian clocks. She also explained how the molecular clock uses small corpuscles and cell space to make our genes rhythm.

Click on the news to  see the video of her brilliant speech.

 

 

 

 

English
Anne-Marie François Bellan

Prof. D. Figarella-Branger, who belongs to the cIMPACT-NOW Working Committee, attended to the last meeting of the consortium in Utrecht (16-17 september).

The cIMPACT-NOW Working Committee is the Consortium to Inform Molecular and Practical Approaches to CNS Tumor Taxonomy. cIMPACT-NOW  was created in late 2016 —following publication of the 2016 Updated 4th Edition of the World Health Organization (WHO) Classification of Tumours of the Central Nervous System— to provide a forum to evaluate and recommend proposed changes to future CNS tumor classifications.

Undefined

Partners